DFDA

Topiramate

Treatment for Idiopathic Epilepsy

Typical Dosage: 100-400 mg daily

Effectiveness
75%
Safety Score
55%
Clinical Trials
1
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
100-400 mg daily
Time to Effect
Weeks to months
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$450
Side Effect Mgmt:$300
Total Annual:$1,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$17,222/QALY
QALYs Gained
4.5
Outcome-Based Costs
Cost per Responder
$3,444
Cost per Remission
$4,429
Topiramate Outcomes

for Idiopathic Epilepsy

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+45%
Remission Rate
+35%
Common Side Effects
Paresthesia
+25%
Cognitive impairment (word-finding difficulty)
+18%
Anorexia/Weight loss
+15%
Fatigue/Somnolence
+15%
Dizziness
+12%
Kidney stones
+2%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
1 completed trial for Topiramate in Idiopathic Epilepsy

Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients

NCT00236886COMPLETEDPHASE3
View Study
49 participants
INTERVENTIONAL
Started: May 1, 1998